BridgeBio Oncology Therapeutics, Inc. - 8-K Filing
BridgeBio Oncology Therapeutics reported $388.9 million in cash and marketable securities as of March 31, 2026, providing a runway into 2028. R&D expenses were $39.8 million for the first quarter compared to $20.6 million in Q1 2025 due to increased clinical trial costs for its three oncology programs (BBO-8520, BBO-11818, and BBO-10203). The company also reported a net loss of $42.1 million compared to $22.1 million in the prior-year period. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $BBOT